1801.HK vs. 1093.HK

Last updated Apr 3, 2026

Compare and contrast key facts about Innovent Biologics Inc (1801.HK) and CSPC Pharmaceutical Group Ltd (1093.HK).

Performance

1801.HK vs. 1093.HK - Performance Comparison

The chart below illustrates the hypothetical performance of a HK$10,000 investment in Innovent Biologics Inc (1801.HK) and CSPC Pharmaceutical Group Ltd (1093.HK). The values are adjusted to include any dividend payments, if applicable.

1801.HK vs. 1093.HK - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
1801.HK Innovent Biologics Inc	20.00%	108.33%	-14.39%	27.61%	-30.57%	-41.19%	209.04%	10.17%	45.36%
1093.HK CSPC Pharmaceutical Group Ltd	15.18%	81.38%	-30.97%	-7.80%	-0.70%	8.57%	-56.88%	65.60%	-31.68%

Returns By Period

In the year-to-date period, 1801.HK achieves a 20.00% return, which is significantly higher than 1093.HK's 15.18% return.

1801.HK

• 1D: 0.66%
• 1M: 14.30%
• YTD: 20.00%
• 6M: -9.14%
• 1Y: 83.55%
• 3Y*: 37.89%
• 5Y*: 2.51%
• 10Y*: —

1093.HK

• 1D: 0.94%
• 1M: 5.31%
• YTD: 15.18%
• 6M: 2.16%
• 1Y: 80.59%
• 3Y*: 12.39%
• 5Y*: 3.90%
• 10Y*: 5.33%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

1801.HK vs. 1093.HK — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

1801.HK

1801.HK Risk / Return Rank: 83
1801.HK Sharpe Ratio Rank: 83
1801.HK Sortino Ratio Rank: 78
1801.HK Omega Ratio Rank: 78
1801.HK Calmar Ratio Rank: 91
1801.HK Martin Ratio Rank: 86

1093.HK

1093.HK Risk / Return Rank: 80
1093.HK Sharpe Ratio Rank: 82
1093.HK Sortino Ratio Rank: 79
1093.HK Omega Ratio Rank: 74
1093.HK Calmar Ratio Rank: 85
1093.HK Martin Ratio Rank: 79

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

1801.HK vs. 1093.HK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Innovent Biologics Inc (1801.HK) and CSPC Pharmaceutical Group Ltd (1093.HK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	1801.HK	1093.HK	Difference
Sharpe ratio Return per unit of total volatility	1.50	1.45	+0.05
Sortino ratio Return per unit of downside risk	2.09	2.14	-0.06
Omega ratio Gain probability vs. loss probability	1.28	1.26	+0.02
Calmar ratio Return relative to maximum drawdown	4.65	3.21	+1.44
Martin ratio Return relative to average drawdown	9.12	6.44	+2.68
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

1801.HK vs. 1093.HK - Sharpe Ratio Comparison

The current 1801.HK Sharpe Ratio is 1.50, which is comparable to the 1093.HK Sharpe Ratio of 1.45. The chart below compares the historical Sharpe Ratios of 1801.HK and 1093.HK, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	1801.HK	1093.HK	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.50	1.45	+0.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.04	0.09	-0.05
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.12	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.45	0.18	+0.26

Correlation

The correlation between 1801.HK and 1093.HK is 0.46, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

1801.HK vs. 1093.HK - Dividend Comparison

1801.HK has not paid dividends to shareholders, while 1093.HK's dividend yield for the trailing twelve months is around 2.47%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
1801.HK Innovent Biologics Inc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
1093.HK CSPC Pharmaceutical Group Ltd	2.47%	2.85%	6.28%	3.44%	2.44%	2.01%	2.36%	0.50%	0.69%	0.40%	0.69%	0.66%

Drawdowns

1801.HK vs. 1093.HK - Drawdown Comparison

The maximum 1801.HK drawdown since its inception was -82.01%, roughly equal to the maximum 1093.HK drawdown of -80.66%. Use the drawdown chart below to compare losses from any high point for 1801.HK and 1093.HK.

Drawdown Indicators

	1801.HK	1093.HK	Difference
Max Drawdown Largest peak-to-trough decline	-82.01%	-80.66%	-1.35%
Max Drawdown (1Y) Largest decline over 1 year	-28.74%	-34.99%	+6.25%
Max Drawdown (5Y) Largest decline over 5 years	-80.16%	-60.67%	-19.49%
Max Drawdown (10Y) Largest decline over 10 years	—	-80.66%	—
Current Drawdown Current decline from peak	-14.49%	-55.51%	+41.02%
Average Drawdown Average peak-to-trough decline	-38.29%	-39.64%	+1.35%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.66%	17.47%	-2.81%

Volatility

1801.HK vs. 1093.HK - Volatility Comparison

The current volatility for Innovent Biologics Inc (1801.HK) is 16.60%, while CSPC Pharmaceutical Group Ltd (1093.HK) has a volatility of 18.87%. This indicates that 1801.HK experiences smaller price fluctuations and is considered to be less risky than 1093.HK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	1801.HK	1093.HK	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.60%	18.87%	-2.27%
Volatility (6M) Calculated over the trailing 6-month period	34.63%	35.83%	-1.20%
Volatility (1Y) Calculated over the trailing 1-year period	57.52%	57.25%	+0.27%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	62.08%	44.69%	+17.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	59.72%	44.24%	+15.48%

Financials